One of the most common points of confusion in GLP-1 research discussions: Ozempic and Wegovy are the same molecule (semaglutide) manufactured by the same company (Novo Nordisk). What differs is the maximum approved dose and the FDA-approved indication. This matters both clinically and for understanding the research literature. This overview specifically addresses ozempic vs wegovy, and related research is indexed on PubMed.
The Key Differences
- Ozempic (semaglutide 0.5mg, 1mg, 2mg): FDA-approved for type 2 diabetes management and cardiovascular risk reduction in adults with T2D and established cardiovascular disease (SELECT trial indication). Maximum dose 2mg/week.
- Wegovy (semaglutide 2.4mg): FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Maximum dose 2.4mg/week.
- Rybelsus (oral semaglutide 3mg, 7mg, 14mg): Daily oral tablet for T2D. Lower bioavailability means much higher dose required for similar plasma levels vs injectable.
Why Dose Matters: The Dose-Response Relationship
The STEP trials established a clear dose-response relationship for weight outcomes with semaglutide. STEP-1 (2.4mg) showed ~14.9% mean body weight reduction. Earlier trials at 1mg showed approximately 6-8% mean weight reduction. This is not a linear relationship — the higher dose produces disproportionately larger weight outcomes, consistent with dose-dependent CNS receptor saturation.
The dose difference also affects side effect prevalence — GI side effects (nausea, vomiting, diarrhea) are more common at higher doses. STEP-1 reported nausea in ~44% of participants at 2.4mg.
The SELECT Trial: Cardiovascular Outcomes
The SELECT trial (published 2023, NEJM) enrolled 17,604 adults with obesity or overweight, established cardiovascular disease, but NO diabetes. Semaglutide 2.4mg reduced MACE (major adverse cardiovascular events — heart attack, stroke, cardiovascular death) by 20% vs placebo over ~3.3 years. This was a landmark result because it demonstrated cardiovascular benefit in a non-diabetic population with obesity — the largest trial of its kind.
The mechanism of cardiovascular benefit is still being characterized. Weight loss alone doesn’t fully explain a 20% MACE reduction in 3.3 years. Anti-inflammatory effects, direct vascular GLP-1R effects, and improved risk factor profiles (blood pressure, lipids, CRP) likely all contribute.
Off-Label and Research Context
The dose distinction matters for understanding research literature: studies using Ozempic doses (≤2mg) will show different weight and CNS outcomes than studies using Wegovy doses (2.4mg). When evaluating published studies, always check the dose used — dose is arguably the most important variable after the compound identity itself.
Why Insurance Coverage Often Differs Between the Two, Despite Being the Same Drug
One of the more practically important consequences of the dose/indication split is insurance coverage behavior. Because Ozempic’s approved indication is type 2 diabetes management, and diabetes medications have historically been covered more consistently by health insurers than obesity medications, patients using semaglutide for its diabetes indication have often found coverage easier to obtain than patients seeking Wegovy specifically for weight management — even though many insurers have since added obesity-medication benefits. This coverage asymmetry has, at times, contributed to physicians prescribing Ozempic off-label for weight loss in patients without diabetes, since it can be more likely to be covered than Wegovy despite functionally overlapping use. This is a payer-policy dynamic rather than a clinical distinction between the two products.
The Compounded Semaglutide Legal Landscape Has Changed Significantly
During the semaglutide supply shortage (roughly 2022 through early 2025), FDA rules allowed 503A and 503B compounding pharmacies to produce compounded semaglutide at scale to fill the supply gap, which is how a large compounded/telehealth semaglutide market emerged. That legal window closed when the FDA declared the semaglutide shortage officially resolved on February 21, 2025. As of mid-2026, compounding semaglutide is only defensible for individualized clinical need documented by a licensed prescriber — 503A pharmacies with valid patient-specific prescriptions can still compound it, but the broad, shortage-based mass-compounding pathway that supplied much of the telehealth market is closed. On April 30, 2026, the FDA went further and proposed permanently excluding semaglutide (along with tirzepatide and liraglutide) from the 503B bulk drug substances list — a proposed rule, still in public comment as of this writing, that would foreclose large-scale bulk compounding of these medications even during a future shortage if finalized. Anyone encountering “compounded semaglutide” offers should understand this narrowing legal environment and the FDA’s active warning-letter enforcement against mass-marketed compounded versions.
Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
In a narrower sense — 503A pharmacies can still compound it for documented individual patient need with a valid prescription, but the broad shortage-based compounding market that existed through early 2025 has closed since the FDA declared the shortage resolved in February 2025, and a proposed April 2026 rule would permanently exclude semaglutide from bulk 503B compounding if finalized.
Why would a doctor prescribe Ozempic for weight loss instead of Wegovy?
Insurance coverage dynamics are a common factor — diabetes-indicated Ozempic has historically had more consistent coverage pathways than the obesity-indicated Wegovy, even though both contain the same semaglutide molecule.
Are Ozempic and Wegovy interchangeable at the same dose?
They’re the same molecule, so a matched dose should behave equivalently, but the two products are approved, labeled, and often insurance-covered for different indications, and prescribers generally follow the approved dosing schedule for the specific product and indication being treated.
Educational content only. Both Ozempic and Wegovy are prescription medications with FDA-approved indications. Not medical advice.
